Westlake N-of-1 Trials for Macronutrient Intake 2 ( WE-MACNUTR 2)

May 27, 2022 updated by: Westlake University

Westlake Personalized Nutrition Intervention Study: N-of-1 Trials for Dietary Macronutrient Intake 2

Diet and nutrition are key to maintain human health. Westlake N-of-1 Trials for Macronutrient Intake (WE-MACNUTR) trial investigates individualized postprandial glycemic responses to different proportions of dietary fat and carbohydrates intake using an n-of-1 experimental study design. The experimental diets are isocaloric high fat, low carbohydrate (HF-LC) or low fat, high carbohydrate (LF-HC). With standardized intervention and strictly controlled eating behaviors, the WE-MACNUTR study identifies specific HC-responders and HF-responders in terms of postprandial glucose response.

This is a follow-up study offered to participants who have completed the WE-MACNUTR study in 2019. Volunteers will be asked to participate in four 5-d periods while wearing glucose monitors (Abbott Freestyle Libre) with the following experimental sequence: 1) a washout diet, 2) HF-LC or LC-HF diet, 3) a washout diet, 4) HF-LC or LC-HF diet. The experimental diet will be randomly assigned. Participants will be asked to provide a fasted blood sample and to collect fecal, urine and saliva samples at each visits.

Study Overview

Detailed Description

This study is a two arm dietary intervention study. Participants will be recruited from the WE-MACNUTR study based on the defined inclusion and exclusion criteria. The study duration will last up to 21 days.

Volunteers will be asked to participate in four 5-day periods while wearing glucose monitors (Abbott Freestyle Libre) with the following experimental sequence: 1) a washout diet, 2) HF-LC or LC-HF diet, 3) a washout diet, 4) HF-LC or LC-HF diet. The experimental diet will be randomly assigned.

Participants will enter the study on a usual (washout) diet and will have a 5-day run in period for baseline data collection. Participants will be asked to follow dietary guidance and consumed a healthy and balanced diet during this period.

Study Type

Interventional

Enrollment (Actual)

11

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Zhejiang
      • Hangzhou, Zhejiang, China, 310024
        • Westlake University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participants have completed WE-MACNUTR trial in 2019
  • Participants have no traveling plans within 1 months
  • Participants are able and willing to comply with the study protocol and provide informed consent

Exclusion Criteria:

  • Refuse or are unable to provide informed consent to participate in the study
  • Have long-term gastrointestinal diseases and take daily relevant medications
  • Have taken antibiotics in the last 2 weeks
  • Have type 2 diabetes and are taking medications or other treatments
  • Have chronic or acute liver disease and are taking medications or other treatments
  • Have cardiovascular diseases and are taking medications or other treatments
  • Have kidney disease and are taking medications
  • Suffer from chronic anxiety or depression, or other critical neuronal disorder and/or history of relevant medication
  • Are pregnant or lactating, or are planning to be pregnant in the next 3 months
  • Diagnosed with an eating disorder (e.g. anorexia nervosa or bulimia nervosa)
  • Are vegan, or unwilling to consume foods provided in the study
  • Have history of alcohol or drug addiction, or smoke above 15 cigarettes per day

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: High fat, low carbohydrate diet
Throughout the 5-day intervention, participants are provided with a high fat, low carbohydrate (HF-LC) diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25%, respectively.
Other Names:
  • HF-LC
Experimental: Low fat, high carbohydrate diet
Throughout the 5-day intervention, participants are provided with a low fat, high carbohydrate (LF-HC) diet in which the percentage of fat, protein and carbohydrate is 10%, 15% and 75%, respectively.
Other Names:
  • LF-HC

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood glucose profiling
Time Frame: 20 days
Real-time blood glucose fluctuations will be recorded by CGM.
20 days

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Urines untargeted metabolomics profiling
Time Frame: Day 6, day 11 day 16 and day 21 of the study
Urine metabolite extracts will be analysed by performing liquid chromatography/quadrupole time-of-flight mass spectrometry (LC/Q-TOF/MS). Compound will be identified by retention time and relative amount.
Day 6, day 11 day 16 and day 21 of the study
Fecal targeted metabolomics profiling
Time Frame: Day 6, day 11 day 16 and day 21 of the study
Fecal metabolite extracts will be analysed by performing liquid chromatography/quadrupole time-of-flight mass spectrometry (LC/Q-TOF/MS). Metabolites, L-alanine for example, will be identified in μmol/L.
Day 6, day 11 day 16 and day 21 of the study
Microbiome taxonomic profiling
Time Frame: Day 6, day 11 day 16 and day 21 of the study
Stool samples will be collected on day 6, day 11 day 16 and day 21 of the study. Shotgun metagenomic sequencing will be performed in stool samples. The taxonomic profiling and the organisms' relative abundance will be quantified using MetaPhlAn.
Day 6, day 11 day 16 and day 21 of the study
Serum metabolomics profile
Time Frame: Day 6, day 11 day 16 and day 21 of the study
Venous blood samples will be collected at fasting in the morning on day 6, day 11 day 16 and day 21 of the study. The liquid chromatography/mass spectrometry (LC/MS) method with targeted metabolomics will be performed in blood serum. Compound (amino acids, fatty acids and bile acids) will be identified by retention time and relative amount.
Day 6, day 11 day 16 and day 21 of the study
Lipid metabolism
Time Frame: Day 6, day 11 day 16 and day 21 of the study
Triglyceride, cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, apolipoprotein A1 and apolipoprotein B will be analyzed at all visits of the study.
Day 6, day 11 day 16 and day 21 of the study
Body composition
Time Frame: Day 5 of the study
Body composition (fat mass, lean mass in kg ) will be assessed by bioelectrical impedance analysis.
Day 5 of the study

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 30, 2021

Primary Completion (Actual)

November 18, 2021

Study Completion (Actual)

November 19, 2021

Study Registration Dates

First Submitted

November 18, 2021

First Submitted That Met QC Criteria

December 2, 2021

First Posted (Actual)

December 17, 2021

Study Record Updates

Last Update Posted (Actual)

June 1, 2022

Last Update Submitted That Met QC Criteria

May 27, 2022

Last Verified

October 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • 20211011ZJS001

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postprandial Hyperglycemia

Clinical Trials on High fat, low carbohydrate diet

Subscribe